Examkin

Question

Difficulty: MediumMonitoring and Treatment Evaluation

A 35-year-old man comes to the clinic for a routine health maintenance visit. He has a history of bipolar I disorder, which has been well-controlled on lithium monotherapy for the past 5 years. He reports no recent manic or depressive episodes and states that his mood has been highly stable. He denies polyuria, polydipsia, fatigue, or unintentional weight changes. He takes no other medications and has no other known medical conditions. Vital signs are within normal limits, and the physical examination is unremarkable. A recent serum lithium level was 0.8 mEq/L0.8 \text{ mEq/L} (therapeutic range: 0.6−1.2 mEq/L0.6-1.2 \text{ mEq/L}). Which of the following laboratory studies are indicated for routine ongoing monitoring of this patient's long-term pharmacotherapy? (Select three)

  1. Serum creatinineAnswer
  2. Thyroid-stimulating hormoneAnswer
  3. Serum calciumAnswer
  4. D
    Alanine aminotransferase
  5. E
    Complete blood count
  6. F
    Hemoglobin A1c

Answer

The correct parameters for ongoing lithium monitoring are serum creatinine, thyroid-stimulating hormone, and serum calcium.
Lithium has a narrow therapeutic index and several well-established, long-term adverse effects affecting specific organ systems. It is primarily excreted unchanged by the kidneys and can cause chronic tubulointerstitial nephropathy or nephrogenic diabetes insipidus, necessitating periodic monitoring of renal function via serum creatinine. Lithium also frequently causes thyroid dysfunction (most commonly hypothyroidism) by interfering with the synthesis and release of thyroid hormones, requiring regular assessment of thyroid-stimulating hormone (TSH). Additionally, lithium can alter calcium metabolism and lead to hypercalcemia via medication-induced hyperparathyroidism; thus, serum calcium levels should also be periodically evaluated. In clinically stable patients on maintenance therapy, these parameters are typically checked every 6 to 12 months.

Step-by-Step Solution

1
Identify the patient's current medication and its known long-term adverse effects.
The patient is on long-term lithium therapy. Chronic lithium use is known to be toxic to the kidneys, the thyroid gland, and the parathyroid glands.
Recognizing the organ-specific toxicity profile of a drug is essential for selecting appropriate, guideline-concordant surveillance tests.
2
Select the specific laboratory tests that screen for these drug-induced organ toxicities.
Serum creatinine evaluates for lithium-induced nephropathy, thyroid-stimulating hormone screens for hypothyroidism, and serum calcium screens for hyperparathyroidism.
Standard psychiatric guidelines mandate periodic monitoring of these exact parameters to detect asymptomatic complications early.
3
Differentiate lithium's monitoring requirements from those of other psychotropic medications.
Tests like transaminases, complete blood counts, and hemoglobin A1c are excluded because they track toxicities of other drug classes.
This prevents ordering unnecessary diagnostic tests and avoids confusing lithium's profile with that of valproate, carbamazepine, or atypical antipsychotics.

Key Concept

Patients on maintenance lithium therapy require periodic monitoring of renal function (serum creatinine/BUN), thyroid function (thyroid-stimulating hormone), and parathyroid function (serum calcium) due to the drug's long-term organ toxicities.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic